Thymidine phosphorylase protein structure
|PDB structures||RCSB PDB PDBe PDBsum|
|Gene Ontology||AmiGO / EGO|
- thymidine + phosphate thymine + 2-deoxy-alpha-D-ribose 1-phosphate
This enzyme belongs to the family of glycosyltransferases, specifically the pentosyltransferases. The systematic name of this enzyme class is thymidine:phosphate deoxy-alpha-D-ribosyltransferase. Other names in common use include pyrimidine phosphorylase, thymidine-orthophosphate deoxyribosyltransferase, animal growth regulators, blood platelet-derived endothelial cell, growth factors, blood platelet-derived endothelial cell growth factor, deoxythymidine phosphorylase, gliostatins, pyrimidine deoxynucleoside phosphorylase, and thymidine:phosphate deoxy-D-ribosyltransferase. This enzyme is involved in metabolic pathways: purine metabolism/pyrimidine metabolism, bladder cancer, and in the diagnosis of mitochondrial neurogastrointestinal encephalomyopathy (MNGIE).
Thymidine phosphorylase catalyzes the reversible phosphorylation of thymidine, deoxyuridine, and their analogs (except deoxycytidine) to their respective bases (thymine/uracil) and 2-deoxyribose 1-phosphate. The enzyme follows a sequential mechanism, where phosphate binds before thymidine (or deoxyuridine, etc.) and 2-deoxyribose 1-phosphate leaves after the nitrogenous base. The thymidine is bound in a high-energy conformation, in which the glycosidic bond weakens as the phosphate attacks the C1 position of the ribose ring, as shown below. The enzyme can then transfer deoxyribose 1-phosphate to other nitrogenous bases.
Further experiments have shown that thymine inhibits the enzyme via both substrate inhibition and nonlinear product inhibition. This suggests that thymine can inhibit the enzyme via multiple sites. The enzyme also displays cooperativity with respect to both thymidine and phosphate in the presence of thymine, which suggests that thymidine phosphorylase has several allosteric and/or catalytic sites as well.
Thymidine phosphorylase is a protein dimer with identical subunits – with a reported molecular weight of 90,000 daltons in Escherichia coli. It has an S-shape with a length of 110 Å and a width of 60 Å. Each monomer is composed of 440 amino acids and is composed of a small α-helical domain and a large α/β domain. The surface of the enzyme is smooth except for a 10 Å deep and 8 Å wide cavity between the two domains that contains the thymine, thymidine, and phosphate binding sites. Detailed analysis of the binding sites shows that Arg-171, Ser-186, and Lys-190 are the important residues in binding the pyrimidine base. The residues Arg-171 and Lys-190 are close to O4 and O2 of the thymine ring, respectively, and can help stabilize the intermediate state. The terminal amino group of Lys-190, which forms a hydrogen bond with the 3′-hydroxyl of the thymidine ribose moiety is also in place to donate a proton to thymine N1 during the intermediate state. As of late 2007, 6 structures have been solved for this class of enzymes, with PDB accession codes 1AZY, 1OTP, 1TPT, 1UOU, 2J0F, and 2TPT.
Thymidine phosphorylase plays a key role in pyrimidine salvage to recover nucleosides after DNA/RNA degradation. Although the reaction it catalyzes between thymidine/deoxyuridine and their respective bases is reversible, the enzyme's function is primarily catabolic.
Recent research has found that thymidine phosphorylase is also involved in angiogenesis. Experiments show inhibition of angiogenic effect by thymidine phosphorylase in the presence of 6-amino-5-chlorouracil, an inhibitor of thymidine phosphorylase, suggesting that the enzymatic activity of thymidine phosphorylase is required for its angiogenic activity. Thymidine phosphorylase has been determined to be almost identical to the platelet-derived endothelial cell growth factor (PD-ECGF). Although the mechanism of angiogenesis by thymidine phosphorylase is not yet known, reports show that the enzyme itself is not a growth factor but indirectly causes angiogenesis by stimulating chemotaxis of endothelial and other cells. Some reports suggest that thymidine phosphorylase promotes endothelial cell growth by reducing levels of thymidine that would otherwise inhibit endothelial cell growth. An alternative explanation is that the enzyme’s products induce angiogenesis. Experiments have found that 2-deoxyribose is an endothelial-cell chemoattractant and angiogenesis-inducing factor, which supports this explanation. Research has found thymidine phosphorylase is involved in angiogenesis during the menstrual cycle. The enzyme's expression in the endometrium is raised by a combination of progesterone and transforming growth factor-β1 and varies over the course of the menstrual cycle.
Mitochondrial neurogastrointestinal encephalomyopathy (MNGIE) is an autosomal recessive disorder caused by mutations in the thymidine phosphorylase (TP) gene. Because mitochondrial DNA (mtDNA) depends strongly on thymidine salvage (more so than nuclear DNA), it suffers damage from thymidine phosphorylase deficiency. In MNGIE disease, multiple deletions and depletion of mtDNA accumulate over time, leading to mitochondrial dysfunction. Symptoms of MNGIE disease include diarrhea and abdominal pain as a result of dysmotility, caused by neuromuscular dysfunction, as well as ptosis, ophthalmoparesis, peripheral neuropathy, and hearing loss.
Thymidine phosphorylase has also been found to play a dual role in both cancer development and therapy. The enzyme's angiogenic activity promotes tumor growth, as supported by research showing much higher expression and activity of thymidine phosphorylase in malignant tumors (including carcinomas in the esophagus, stomach, colorectum, pancreas, and lung) than in adjacent non-neoplastic tissues  Thymidine phosphorylase in these carcinomas is up-regulated by cytokines interferon-γ and TNF-α, which are released by inflammatory cells during wound healing. The enzyme is also up-regulated by low oxygen levels and low pH environments in order to control vascularization of hypoxic regions.
However, thymidine phosphorylase has also been found to play an essential role in the activation of the anti-cancer drug capecitabine. Specifically, it converts the intermediate metabolite 5’-deoxy-5-fluorocytidine in tumors to 5-fluorouracil, which acts as a thymidylate synthase inhibitor.
- Norman, RA; Barry, ST; Bate, M; Breed, J; Colls, JG; Ernill, RJ; Luke, RW; Minshull, CA; McAlister, MS; McCall, EJ; McMiken, HH; Paterson, DS; Timms, D; Tucker, JA; Pauptit, RA (January 2004). "Crystal structure of human thymidine phosphorylase in complex with a small molecule inhibitor.". Structure (London, England : 1993). 12 (1): 75–84. doi:10.1016/j.str.2003.11.018. PMID 14725767.
- Iltzsch, MH; el Kouni, MH; Cha, S (19 November 1985). "Kinetic studies of thymidine phosphorylase from mouse liver.". Biochemistry. 24 (24): 6799–807. doi:10.1021/bi00345a011. PMID 4074727.
- Walter, MR; Cook, WJ; Cole, LB; Short, SA; Koszalka, GW; Krenitsky, TA; Ealick, SE (15 August 1990). "Three-dimensional structure of thymidine phosphorylase from Escherichia coli at 2.8 A resolution.". The Journal of Biological Chemistry. 265 (23): 14016–22. PMID 2199449.
- Pugmire, MJ; Cook, WJ; Jasanoff, A; Walter, MR; Ealick, SE (14 August 1998). "Structural and theoretical studies suggest domain movement produces an active conformation of thymidine phosphorylase.". Journal of Molecular Biology. 281 (2): 285–99. doi:10.1006/jmbi.1998.1941. PMID 9698549.
- LaFon, SW; Nelson, DJ; Berens, RL; Marr, JJ (15 January 1982). "Purine and pyrimidine salvage pathways in Leishmania donovani.". Biochemical Pharmacology. 31 (2): 231–8. doi:10.1016/0006-2952(82)90216-7. PMID 7059364.
- Desgranges, C; Razaka, G; Rabaud, M; Bricaud, H (27 July 1981). "Catabolism of thymidine in human blood platelets: purification and properties of thymidine phosphorylase.". Biochimica et Biophysica Acta. 654 (2): 211–8. doi:10.1016/0005-2787(81)90174-x. PMID 7284378.
- Haraguchi, M; Miyadera, K; Uemura, K; Sumizawa, T; Furukawa, T; Yamada, K; Akiyama, S; Yamada, Y (17 March 1994). "Angiogenic activity of enzymes.". Nature. 368 (6468): 198. doi:10.1038/368198a0. PMID 7511797.
- Miyadera, K; Sumizawa, T; Haraguchi, M; Yoshida, H; Konstanty, W; Yamada, Y; Akiyama, S (15 April 1995). "Role of thymidine phosphorylase activity in the angiogenic effect of platelet derived endothelial cell growth factor/thymidine phosphorylase.". Cancer Research. 55 (8): 1687–90. PMID 7536129.
- Finnis, C; Dodsworth, N; Pollitt, CE; Carr, G; Sleep, D (15 February 1993). "Thymidine phosphorylase activity of platelet-derived endothelial cell growth factor is responsible for endothelial cell mitogenicity.". European Journal of Biochemistry / FEBS. 212 (1): 201–10. doi:10.1111/j.1432-1033.1993.tb17651.x. PMID 8444155.
- Li, W; Chiba, Y; Kimura, T; Morioka, K; Uesaka, T; Ihaya, A; Muraoka, R (February 2001). "Transmyocardial laser revascularization induced angiogenesis correlated with the expression of matrix metalloproteinases and platelet-derived endothelial cell growth factor.". European Journal of Cardio-Thoracic Surgery. 19 (2): 156–63. doi:10.1016/s1010-7940(00)00649-7. PMID 11167105.
- Hague, S; Manek, S; Oehler, MK; MacKenzie, IZ; Bicknell, R; Rees, MC (4 March 2002). "Tamoxifen induction of angiogenic factor expression in endometrium.". British Journal of Cancer. 86 (5): 761–7. doi:10.1038/sj.bjc.6600157. PMC . PMID 11875740.
- Nishino, I; Spinazzola, A; Hirano, M (29 January 1999). "Thymidine phosphorylase gene mutations in MNGIE, a human mitochondrial disorder.". Science. 283 (5402): 689–92. doi:10.1126/science.283.5402.689. PMID 9924029.
- Hirano, M; Pagon, RA; Adam, MP; Ardinger, HH; Wallace, SE; Amemiya, A; Bean, LJH; Bird, TD; Fong, CT; Mefford, HC; Smith, RJH; Stephens, K (1993). "Mitochondrial Neurogastrointestinal Encephalopathy Disease". PMID 20301358.
- Nishino, I; Spinazzola, A; Papadimitriou, A; Hammans, S; Steiner, I; Hahn, CD; Connolly, AM; Verloes, A; Guimarães, J; Maillard, I; Hamano, H; Donati, MA; Semrad, CE; Russell, JA; Andreu, AL; Hadjigeorgiou, GM; Vu, TH; Tadesse, S; Nygaard, TG; Nonaka, I; Hirano, I; Bonilla, E; Rowland, LP; DiMauro, S; Hirano, M (June 2000). "Mitochondrial neurogastrointestinal encephalomyopathy: an autosomal recessive disorder due to thymidine phosphorylase mutations.". Annals of Neurology. 47 (6): 792–800. doi:10.1002/1531-8249(200006)47:6<792::aid-ana12>3.3.co;2-p. PMID 10852545.
- Bronckaers, A; Gago, F; Balzarini, J; Liekens, S (November 2009). "The dual role of thymidine phosphorylase in cancer development and chemotherapy.". Medicinal Research Reviews. 29 (6): 903–53. doi:10.1002/med.20159. PMID 19434693.
- Takebayashi, Y; Yamada, K; Miyadera, K; Sumizawa, T; Furukawa, T; Kinoshita, F; Aoki, D; Okumura, H; Yamada, Y; Akiyama, S; Aikou, T (June 1996). "The activity and expression of thymidine phosphorylase in human solid tumours.". European journal of cancer (Oxford, England : 1990). 32A (7): 1227–32. PMID 8758258.
- Brown, NS; Bicknell, R (15 August 1998). "Thymidine phosphorylase, 2-deoxy-D-ribose and angiogenesis.". The Biochemical Journal. 334 (1): 1–8. doi:10.1042/bj3340001. PMC . PMID 9693094.
- Sawada, N; Ishikawa, T; Fukase, Y; Nishida, M; Yoshikubo, T; Ishitsuka, H (April 1998). "Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by taxol/taxotere in human cancer xenografts.". Clinical Cancer Research. 4 (4): 1013–9. PMID 9563897.
- FRIEDKIN M, ROBERTS D (1954). "The enzymatic synthesis of nucleosides. I. Thymidine phosphorylase in mammalian tissue". J. Biol. Chem. 207 (1): 245–56. PMID 13152099.
- Zimmerman M; Seidenberg J (1964). "Deoxyribosyl transfer. I. Thymidine phosphorylase and nucleoside deoxyribosyltransferase in normal and malignant tissues". J. Biol. Chem. 239: 2618–2621. PMID 14235544.
- Zimmerman M (1964). "Deoxyribosyl transfer. II. Nucleoside:pyrimidine deoxyribosyltransferase activity of three partially purified thymidine phosphorylases". J. Biol. Chem. 239: 2622–2627. PMID 14235545.